Document is current
Any future updates will be listed below
-
Authors
Coates, Laura C https://orcid.org/0000-0002-4756-663X
Gossec, Laure https://orcid.org/0000-0002-4528-310X
Zimmermann, Miriam https://orcid.org/0000-0001-6063-3000
Shawi, May
Rampakakis, Emmanouil https://orcid.org/0000-0002-7427-8246
Shiff, Natalie J
Kollmeier, Alexa P
Xu, Xie L
Nash, Peter https://orcid.org/0000-0002-2571-788X
Mease, Philip J https://orcid.org/0000-0002-6620-0457
Helliwell, Philip S https://orcid.org/0000-0002-4155-9105
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03158285 at ClinicalTrials.govnct03158285 at ClinicalTrials.govDocuments that mention this clinical trial
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
https://doi.org/10.1136/rmdopen-2021-001679
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40264-023-01361-w
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
https://doi.org/10.1136/rmdopen-2022-002195
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
https://doi.org/10.1136/rmdopen-2022-002934
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
https://doi.org/10.1007/s40744-023-00592-8
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/rmdopen-2023-003977
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
https://doi.org/10.1007/s40744-022-00444-x
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-024-00642-9
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
https://doi.org/10.1007/s12325-022-02269-0
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002789
Documents that mention this clinical trial
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
https://doi.org/10.1136/rmdopen-2021-001679
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40264-023-01361-w
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
https://doi.org/10.1136/rmdopen-2022-002195
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
https://doi.org/10.1136/rmdopen-2022-002934
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
https://doi.org/10.1007/s40744-023-00592-8
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/rmdopen-2023-003977
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
https://doi.org/10.1007/s40744-022-00444-x
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-024-00642-9
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
https://doi.org/10.1007/s12325-022-02269-0
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002789
-
Funding
Funding for this research was provided by:
Janssen Research & Development, LLC, Spring House, PA
- License Information
